Biotage Universal Phase Separators, Solving an Age Old Problem
Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced their new Universal Phase Separators, a flexible alternative to the traditional glass funnel separation of immiscible liquids.
Uppsala, Sweden, November 15, 2012 / B3C newswire / - Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced their new Universal Phase Separators, a flexible alternative to the traditional glass funnel separation of immiscible liquids. The Biotage Universal Phase Separation columns are fitted with a selectively permeable insert that separates aqueous phases from organic solvents under gravity; solving the age old problem of how to remove an upper organic phase from a lower aqueous phase, during a traditional liquid-liquid extraction process, without creating additional process steps.
The unique design allows the organic phase to pass through the internal frit wherever it is located, providing a universal approach to separating two liquid phases while its one-size-fits-all approach enables any volume under 80 mL to be processed in one step, or larger volumes by serial batches. Made from inert proprietary polymers, the Biotage Universal Phase Separators come in an easy-to-use kit form and refill packs, ready to use in seconds straight out of the box.
"Biotage Universal Phase Separators are the modern day alternative to separating with the glass separating funnel. Ideal for working with a range of organic solvents, or in parallel this product is economical, flexible and extremely simple to use. There are no moving parts, with nothing to prime, it's all achieved by fundamental physical principles and clever product design." says Dr. Sunil Rana, Product Manager Chemistry Applications and Resins and Work-Up Products at Biotage.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.